Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna shared new data which shows that a 50 microgram dose of its booster vaccine increases the level of neutralizing antibodies 37-fold.

Moderna says its booster significantly increases antibody levels against the Omicron variant

Modern described the findings as reassuring, but said it will also continue to develop an omicron-specific booster candidate.

Moderna says booster of its Covid vaccine appears to protect against omicron

Moderna's findings come days after studies indicated that a standard two-dose regimen of the vaccine has lower efficacy in tackling the omicron variant.

Moderna Says Its Covid-19 Booster Dose Offers Strong Protection Against Omicron

Moderna said Monday that preliminary data showed that a 50 microgram booster dose of its COVID vaccine triggered a 37-fold rise in neutralizing antibodies against the omicron variant of coronavirus. Tests also showed that a 100 microgram dose increased those neutralizing antibodies 83-fold against omicron, the company said in a statement.

Moderna says third dose of its COVID vaccine offers higher protection against omicron

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant

Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant

The pharmaceutical giant says government scientists shouldn't be credited on a patent for a key ingredient in the vaccine, meaning the company wouldn't have to pay out billions in royalties.

Moderna Drops Covid-19 Vaccine Patent Application, Cooling Legal Fight With Government

Rivian Automotive

Slack

3 Stocks Trading at a Discount Right Now: These Investors Are Still Skeptical About Buying

Johnson & Johnson

Pfizer

J&J is still available, but most people should choose Pfizer or Moderna for their vaccine or booster shot, the CDC says.

CDC recommends Moderna, Pfizer vaccines over Johnson & Johnson's

Mixing and matching vaccines could go in the company's favor.

This New Study Could Give Moderna a Big Advantage in 2022

A panel that advises the CDC says the agency should adopt the recommendation because of a rare but dangerous blood-clotting disorder that's been linked to the J&J vaccine.

CDC committee recommends Moderna, Pfizer vaccines over Johnson & Johnson's

An influential advisory committee burnishes the reputations of the two companies' coronavirus vaccines, while one gets a glowing write-up about its COVID-19 pill.

Why Moderna and Pfizer Beat the Market Today

The CDC has not yet decided if it will accept the recommendation and remove the shot from the market.

Moderna, Pfizer Covid Vaccines Should Be Given Over Johnson & Johnson's, CDC Advisory Board Says

BioNTech SE

Novavax

All of these vaccine stocks benefited from rising concerns about the Omicron variant.

Why Novavax, BioNTech, and Moderna Stocks Are Jumping This Week

The Centers for Disease Control and Prevention recommended Pfizer and Moderna Covid vaccines over the Johnson & Johnson vaccine.

CDC expert panel prefers Pfizer, Moderna vaccines over J&J shots for adults due to rare blood clot cases

Moderna stock has seen a fair bit of volatility, declining by over 20% since early December. The sell-off comes amid the spread of the highly infectious omicron variant of the coronavirus.

Flu Vaccine And Omicron Uncertainty Weighs On Moderna Stock. Time To Buy?

Bath and Body Works

Devon Energy

Ford Motor Company

Diamondback Energy

Fortinet

Marathon Oil

NVIDIA

The year 2021 has featured retail trading-induced short squeezes, soaring special purpose acquisition companies (SPACs) and extreme volatility in cryptocurrency markets. Amid the many bouts of short-term mania, there are a handful of stocks in the S&P 500 Index that have more than doubled this year.

8 S&P 500 Stocks Up More Than 100% In 2021

The Omicron variant has made Wuhan based vaccines redundant, will replace Delta, and causes a milder version of covid. BioNTech, Novavax and Moderna will need to urgently develop an appropriate 2nd generation vaccine candidate.

COVID-19 Vaccines: The Big Omicron Reboot For BioNTech, Moderna And Novavax

The mRNA shots were around 20% effective at preventing infection with delta in males over age 65 months five through seven after completing vaccination.

Pfizer, Moderna Vaccines Less Effective Against Delta In Elderly And Protection Wanes Rapidly Four Months After Second Covid Shot, Study Finds

C3.ai

Continental Resources

GameStop

GoHealth, Inc.

Paysafe

Peloton

StoneCo

Upstart Holdings

GameStop, Upstart, Moderna, Devon Energy, and Continental Resources are the top stocks of the year. The bottom 5 are Peloton, GoHealth, Paysafe, C3.ai, and StoneCo.

The Top (and Bottom) 5 Stocks of 2021

Moderna dropped after results for its mRNA flu vaccine underwhelmed investors. That proves MRNA stock is suffering from short-term thinking.

Moderna's Long-Term Benefit Is Cursed by Short-Term Thinking

Moderna Inc (NASDAQ: MRNA) agreed in principle with the Australian government to build a messenger RNA (mRNA) vaccine manufacturing facility in Victoria, Australia, including access to Moderna's mRNA development engine.  The Australian Prime Minister Scott Morrison said the plant in Victoria state was expected to produce up to 100 million mRNA vaccine doses every year when it begins operations in 2024.

Moderna, Australia Collaborate To Bring mRNA Manufacturing To Australia

CAMRIDGE, Mass.--(BUSINESS WIRE)--Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia

Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia

Tesla

The market moved lower ahead of a key central bank meeting later this week.

Dow Drops More Than 300 Points Ahead Of Fed Meeting, Tesla Sinks While Pfizer, Moderna Jump

Moderna's (MRNA) early-stage flu vaccine data seems promising but it fails to meet investors' expectations.

News for Moderna Stock (MRNA)